Yoshikazu Yuki, Shiho Kurokawa, Kotomi Sugiura, Koji Kashima, Shinichi Maruyama, Tomoyuki Yamanoue, Ayaka Honma, Mio Mejima, Natsumi Takeyama, Masaharu Kuroda, Hiroko Kozuka-Hata, Masaaki Oyama, Takehiro Masumura, Rika Nakahashi-Ouchida, Kohtaro Fujihashi, Takashi Hiraizumi, Eiji Goto, Hiroshi Kiyono
We previously established the selection-marker-free rice-based oral cholera vaccine (MucoRice-CTB) line 51A for human use by Agrobacterium -mediated co-transformation and conducted a double-blind, randomized, placebo-controlled phase I trial in Japan and the United States. Although MucoRice-CTB 51A was acceptably safe and well tolerated by healthy Japanese and U.S. subjects and induced CTB-specific antibodies neutralizing cholera toxin secreted by Vibrio cholerae , we were limited to a 6-g cohort in the U.S...
2024: Frontiers in Plant Science